Article

Impact of Type II LRRK2 inhibitors on signalling and mitophagy

2021-05-22

Abstract excerpt

Much effort has been devoted to the development of selective inhibitors of the LRRK2 as a potential treatment for LRRK2 driven Parkinson’s disease. In this study we first compare the properties of Type I (GSK3357679A and MLi-2) and Type II (GZD-824, Rebastinib and Ponatinib) kinase inhibitors that bind to the closed or open conformations of the LRRK2 kinase domain, respectively. We show that Type I and Type II inh...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f702f8cc-a9ac-555e-8720-b1caeccc32ae
DOI: 10.1101/2021.05.21.445132

Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest

Impact of Type II LRRK2 inhibitors on signalling and mitophagyDOI 10.1101/2021.05.21.445132Read

Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.Semantic proximity Read

Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structuresSemantic proximity Read

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.Semantic proximity Read

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.Semantic proximity Read

Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.Semantic proximity Read

Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.Semantic proximity Read

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).Semantic proximity Read

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)Semantic proximity Read

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.Semantic proximity Read

The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.Semantic proximity Read

Impact of 100 LRRK2 variants linked to Parkinson’s Disease on kinase activity and microtubule bindingSemantic proximity Read

G2019S LRRK2 Kinase Inhibition in Heterozygous Mice Avoids Lung Phenotype Observed with Inhibition of WT LRRK2.Semantic proximity Read